Payment overview · 2025
General Payments
$287.93
14 reported records · 6 companies
Healthcare provider profile · identity verified
Suzanne Ware, PA-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · BRADENTON, FL · NPI 1265549083
Verified facts
What the public records show
CMS Open Payments records show Suzanne Ware, PA-C received $287.93 in general payments during 2025 across 14 reported records.
GlaxoSmithKline, LLC. accounted for 33.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $95.23 | 33.1% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $51.97 | 18.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $45.65 | 15.8% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $45.60 | 15.8% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $25.22 | 8.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $24.26 | 8.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $287.93 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $95.23 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $45.60 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $38.29 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $25.22 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $24.26 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $24.24 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.41 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 80 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 42 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
42 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
80 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 283 | 109 |
| Levothyroxine Sodium | Levothyroxine Sodium | 239 | 100 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 225 | 85 |
| Lisinopril | Lisinopril | 215 | 83 |
| Amlodipine Besylate | Amlodipine Besylate | 198 | 85 |
| Omeprazole | Omeprazole | 192 | 64 |
| Losartan Potassium | Losartan Potassium | 153 | 62 |
| Metformin Hcl | Metformin Hcl | 150 | 63 |
| Trazodone Hcl | Trazodone Hcl | 143 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 140 | 57 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 136 | 51 |
| Furosemide | Furosemide | 136 | 58 |
| Donepezil Hcl | Donepezil Hcl | 117 | 31 |
| Gabapentin | Gabapentin | 115 | 57 |
| Tramadol Hcl | Tramadol Hcl | 112 | 48 |
| Prednisone | Prednisone | 111 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 111 | 47 |
| Alprazolam | Alprazolam | 109 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 104 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 96 | 33 |
| Glipizide | Glipizide | 90 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 89 | 33 |
| Ozempic | Semaglutide | 80 | 24 |
| Simvastatin | Simvastatin | 78 | 35 |
| Sertraline Hcl | Sertraline Hcl | 76 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 24 |
| Meloxicam | Meloxicam | 75 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 74 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 70 | 26 |
| Eliquis | Apixaban | 69 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 28 |
| Alendronate Sodium | Alendronate Sodium | 66 | 23 |
| Azithromycin | Azithromycin | 66 | 53 |
| Potassium Chloride | Potassium Chloride | 66 | 31 |
| Lorazepam | Lorazepam | 63 | 14 |
| Montelukast Sodium | Montelukast Sodium | 59 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 58 | 45 |
| Famotidine | Famotidine | 48 | 26 |
| Ezetimibe | Ezetimibe | 47 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 19 |
| Methylprednisolone | Methylprednisolone | 43 | 36 |
| Oxybutynin Chloride | Oxybutynin Chloride | 43 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 43 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | 15 |
| Carvedilol | Carvedilol | 41 | 14 |
| Cephalexin | Cephalexin | 41 | 35 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 41 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 38 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | 11 |
| Temazepam | Temazepam | 35 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 33 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | 16 |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | 12 |
| Allopurinol | Allopurinol | 30 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 30 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 29 | 14 |
| Sildenafil Citrate | Sildenafil Citrate | 29 | 11 |
| Finasteride | Finasteride | 28 | 11 |
| Ondansetron Odt | Ondansetron | 28 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 15 |
| Topiramate | Topiramate | 26 | 11 |
| Valacyclovir | Valacyclovir Hcl | 26 | 15 |
| Pregabalin | Pregabalin | 25 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | 14 |
| Spironolactone | Spironolactone | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 17 |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Nystatin | Nystatin | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 20 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 17 |
| Ibu | Ibuprofen | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Tobramycin | Tobramycin | 17 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 16 |
| Fluconazole | Fluconazole | 16 | 11 |
| Jardiance | Empagliflozin | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 15 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $287.93 · 14 records | GlaxoSmithKline, LLC. | AIRSUPRA, AUSTEDO XR, BREZTRI, GEMTESA, Ozempic, REPATHA, TRELEGY ELLIPTA, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error